Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease

Gut

Volumn 53, Issue 5, 2004, Pages 701-709

  Kirkegaard, T ^b   Hansen, A ^b   Bruun, E ^b   Brynskov, J ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADOLESCENT; ADULT; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLON FISTULA; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ZYMOGRAPHY;

ADOLESCENT; ADULT; COLON; CROHN DISEASE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INTESTINAL FISTULA; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 2342417829     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.017442     Document Type: Article

References (40)

1. Schwartz D, Loftus E, Tremaine W, et al. The natural history of fistulizing Crohn's disease: a population based study. Gastroenterology 2002;122:875-80.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
3. Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2002;120:1640-56.
4. Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut 2002;49(suppl IV):iv2-10.
5. Levy C, Tremaine WJ. Management of internal fistulae in Crohn's disease. Inflamm Bowel Dis 2002;8:106-11.
6. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-25.
7. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88.
8. Gasché C, Schölmerich J, Brynskov J, et al. A simple classification of Crohn's disease: Report of the Working Party for the World Congress of Gastroenterology, Vienna. Inflamm Bowel Dis 2000;6:8-15.
9. Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop Scand Suppl 1995;266:55-60.
10. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
11. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
12. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22.
13. Baugh MD, Evans GS, Hollander AP, et al. Expression of matrix metalloproteases in inflammatory bowel disease. Ann N Y Acad Sci 1998;859:249-53.
14. Arihiro S, Ohtoni H, Hiwatoshi N, et al. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 2001;39:50-9.
15. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
16. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-6.
17. Heuschkel RB, MacDonald TT, Monteleane G, et al. Imbalance of stromelysin and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57-62.
18. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collogenase in Crohn's disease and normal intestine. J Clin Pathol 1994;47:113-16.
19. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996;148:519-26.
20. Vaalama M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastose (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998;152:1005-14.
21. Pender SLF, Tickle SP, Docherty AJP, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
22. Munkhalm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992;27:609-14.
23. Cotan RS, Kumar V, Collins TC. Acute and chronic inflammation. In: Catan RS, Kumar V, Collins T, eds. Robins - Pathologic basis of disease. Philadelphia: WB Saunders, 1999:50-88.
24. Wright NA. The response to injury. In: McGee JO, Isaacsan PG, Wright NA, eds. Oxford textbook of pathology. Oxford: Oxford University Press, 1992:349-406.
25. Vergara E, Gómez-Morales M, Osuna A, et al. Immunohistochemical quantification of leukocyte subsets in the long-term prognosis of kidney transplants. Transplant Proc 1998;30:2380-3.
26. Holm-Bentzen M, Jacobsen F, Nerstrøm B, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol 1987;138:503-7.
27. Mirostschijski U, Impala U, Karsdal MA, et al. Matrix metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo. J Invest Dermatol 2002;118:55-64.
28. Callier IE, Wilhelm SM, Eisen AZ, et al. H-ros oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988;263:6579-87.
29. Kikuchi R, Noguchi T, Takeno S, et al. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 2000;83:215-18.
30. Poulsom R, Pignatelli M, Stetler-Stevensan WG, et al. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasmia. Am J Pathol 1992;141:389-96.
31. Tryggvason K, Höyhtö M, Pyke M. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-18.
32. Pyke C, Ralfkiaer E, Tryggvason K, et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993;142:359-65.
33. Murphy G, Cockett MI, Ward RV, et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991;277:277-9.
34. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704.
35. Hasty KA, Reife RA, Kang AH, et al. The role of stromelysin in the cortilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 1990;33:388-97.
36. Pender SLF, Fell JME, Chamow SM, et al. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160:4098-103.
37. Salmela MT, MacDanald TT, Black D, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridization. Gut 2002;51:540-7.
38. Kim J, Yu W, Kovalski K, et al. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998;94:353-62.
39. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
40. Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucasa of patients with inflammatory bowel disease. Gut 2002;51:37-43.